Clinical Study to Evaluate the Possible Efficacy of Metformin in Patients With Parkinson's Disease

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05781711

Enrollment

Registered

2023-03-23

Start date

2023-01-06

Completion date

2025-01-20

Last updated

2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson Disease

Brief summary

Parkinson's disease (PD) is one of the most common neurodegenerative diseases characterized by the progressive loss of dopaminergic (DA) neurons in the substantia nigra compacta (SNc) and aggregation of Lewy bodies in neurons. Although aging, oxidative damage and neuroinflammation have been recognized to play crucial roles in the pathogenesis of PD, the precise etiology remains obscure. Emerging evidence suggests PD is a systemic metabolic disease, and metabolic abnormality correlates with functional alternations in PD

Interventions

DRUGlevodopa-carbidopa

levodopa-carbidopa is the standard therapy used in Parkinson's disease

DRUGMetformin

Metformin, a biguanide family member commonly used in treatment for type 2 diabetes, appears to increase liver and peripheral tissue sensitivity to insulin as well as reduce hepatic glucose production

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Masking description

double-blind

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

Age ≥ 18 years Both males and females will be included Negative pregnancy test and effective contraception. Diagnosed Parkinson's disease patient taking Levodopa

Exclusion criteria

Secondary causes of Parkinsonism Diabetic patients Patients taking anti-inflammatory drugs Atypical parkinsonian syndromes Prior stereotaxic surgery for Parkinson's disease Pregnancy and lactation Suffering from active malignancy Addiction to alcohol and/or drugs Known allergy to the studied medications

Design outcomes

Primary

Measure	Time frame	Description
• The primary endpoint is the change in The Unified Parkinson's Disease Rating Scale (UPDRS)	3 months	• The primary endpoint is the change in the Unified Parkinson's Disease Rating Scale (UPDRS

Secondary

Measure	Time frame	Description
The secondary endpoint is estimated by changes in serum biomarkers.	3 months	The secondary endpoint is estimated by changes in serum biomarkers such as brain derived neurotropic factor

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026